Hong Kong

The primary regulatory authority for health products in Hong Kong is the Pharmacy and Poisons Board (PPB), operating under the Department of Health. Pharmaceuticals are governed by the Pharmacy and Poisons Ordinance (Cap. 138), while medical devices are regulated under the Medical Device Administrative Control System (MDACS), a voluntary scheme transitioning toward a mandatory framework. The Drug Office under the Department of Health is responsible for the registration of pharmaceutical products, and the Medical Device Control Office (MDCO) oversees devices. Approval processes differ by product type: pharmaceuticals require full registration with clinical, safety, and quality data, while medical devices are classified into risk-based tiers (Class I to IV) with corresponding conformity assessment requirements.

For pharmaceutical submissions, Hong Kong accepts dossiers in the Common Technical Document (CTD) format and places significant weight on prior approvals from recognized reference agencies, including the US FDA, EMA, UK MHRA, Australian TGA, and Health Canada, among others. A local Authorized Seller of Poisons or a licensed importer is required to act as the local responsible party for registered products. The MDACS for medical devices accepts international conformity marks such as CE, FDA 510(k)/PMA, and TGA clearances as supporting evidence. Hong Kong has signaled intentions to strengthen mandatory oversight of medical devices and digital health tools, with ongoing legislative consultations aimed at introducing a more formal statutory registration regime for devices and in vitro diagnostics.

Public sector procurement in Hong Kong is centrally coordinated through the Hospital Authority (HA), a statutory body that manages all public hospitals and clinics in the territory. The HA conducts formulary listing processes and centralized tendering for pharmaceuticals, medical devices, and diagnostics used across its network. Products must be registered with the Drug Office or approved under the relevant regulatory pathway before consideration for HA procurement. Tender evaluation is based on clinical value, quality standards, pricing, and supplier reliability. The Government Logistics Department (GLD) also plays a role in broader government supply procurement, but health-specific procurement is predominantly managed directly by the HA through its pharmaceutical and materials management divisions.

The private healthcare sector in Hong Kong is substantial and operates independently of HA procurement, with private hospitals, clinics, and retail pharmacies sourcing products through local distributors and importers. There is no mandatory local manufacturing preference policy, reflecting Hong Kong's status as a free-trade, import-oriented economy. Donor-funded procurement channels such as UNICEF, the Global Fund, USAID, or Gavi are not applicable to Hong Kong given its high-income status. Digital health products and Software as a Medical Device (SaMD) are an emerging focus, with the MDCO issuing administrative guidance on their classification and oversight, and the government actively promoting health innovation through initiatives linked to the Hong Kong Smart City Blueprint.